2. Search Result
Search Result
Results for "

Gastric mucosa

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

2

Peptides

3

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0261
    Pentagastrin
    1 Publications Verification

    ICI-50123

    		 Cholecystokinin Receptor Endocrinology Cancer
    Pentagastrin (ICI-50123) is a potent, selective Cholecystokinin B (CCKB) receptor antagonists with IC50 values of 11 nM and 1100 nM for CCKB and CCKA, respectively. Pentagastrin enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury . .
    Pentagastrin
  • HY-106449
    Recoflavone

    DA-6034 free acid

    		 Others Inflammation/Immunology Cancer
    Recoflavone is a synthetic derivative of eupatilin that has a protective effect on gastric mucosa. Recoflavone has the potential to be used to research peptic ulcer disease.
    Recoflavone
  • HY-15035
    S-Diclofenac

    ACS 15; ATB-337

    		 COX Inflammation/Immunology
    S-Diclofenac is a hybrid molecule of an H2S donor and the NSAID diclofenac. S-Diclofenac spares the gastric mucosa of injury despite markedly suppressing prostaglandin synthesis .
    S-Diclofenac
  • HY-B0360
    Rebamipide
    3 Publications Verification

    OPC12759; Proamipide

    		 COX Inflammation/Immunology Cancer
    Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer .
    Rebamipide
  • HY-160984
    Rotraxate

    TEI 5103; TG 51

    		 Others Endocrinology
    Rotraxate (TEI 5103) is an orally active anti-ulcer compound. Rotraxate can increase blood flow to the gastric mucosa and promote the integrity of the gastric mucosa. Rotraxate can be used to study the protective effects of drugs on the gastric mucosa, especially in investigating how drugs can prevent or treat gastric ulcers by acting directly on the gastric mucosa .
    Rotraxate
  • HY-A0261A
    Pentagastrin meglumine

    ICI-50123 meglumine

    		 Cholecystokinin Receptor Endocrinology Cancer
    Pentagastrin (ICI-50123) meglumine is a potent, selective Cholecystokinin B (CCKB) receptor antagonists with IC50 values of 11 nM and 1100 nM for CCKB and CCKA, respectively. Pentagastrin meglumine enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury . .
    Pentagastrin meglumine
  • HY-129471
    Arbaprostil

    		Endogenous Metabolite Inflammation/Immunology
    Arbaprostil is an orally active PGE1 (HY-B0131) analog. Arbaprostil protects the gastrointestinal mucosa from stomach acid and other irritants, promotes healing rate of gastric ucler through the antisecretory effect .
    Arbaprostil
  • HY-129424
    Mezolidon

    KM-1146

    		 Others Inflammation/Immunology
    Mezolidon (KM-1146) is a compound with anti-ulcer activity, which exerts its anti-ulcer activity by enhancing the defense ability of gastric mucosa, especially by increasing and maintaining gastric mucosal blood flow and protecting gastric mucosal potential difference. Mezolidon can be used for the study of gastric mucosal protection .
    Mezolidon
  • HY-137273
    Sucrose octasulfate sodium

    		Others Others
    Sucrose octasulfate is a component of sulfoaluminum. Sucrose octasulfate stimulates the release of somatostatin-like immunoreactivity (SLI) from the stomach by acting directly on D cells in the gastric mucosa. Sucrose octasulfate exerts its ulcer-healing effect by releasing endogenous gastric somatostatin Sucrose octasulfate can be used for anti-gastric ulcer research .
    Sucrose octasulfate sodium
  • HY-119762
    Spizofurone

    AG-629

    		 Others Cardiovascular Disease
    Spizofurone is an anti-ulcer compound with increased gastric mucosal blood flow activity and oral activity. Spizofurone has a similar mechanism of action to PGE2 (HY-101952), Spizofurone is capable of acting through local and systemic pathways and may promote ulcer healing by improving blood supply to the gastric mucosa. Spizofurone can be used to study the development strategy of gastric ulcer .
    Spizofurone
  • HY-B0796
    Bismuth potassium citrate
    Maximum Cited Publications
    24 Publications Verification

    Bismuth tripotassium dicitrate; Bismuth subcitrate

    		 Bacterial Infection Inflammation/Immunology Cancer
    Bismuth potassium citrate (Bismuth tripotassium dicitrate) is an orally active gastric mucosal protector and has antibacterial and anti-inflammatory activity. Bismuth potassium citrate relieves stomach pain, resists H. pylori growth and repairs gastric mucosa. Bismuth potassium citrate combined with Omeprazole (HY-B0113) has a safe and high efficacy against H. pylori infection, which is promising for research of peptic ulcers, gastric cancer and tubulointerstitial nephritis .
    Bismuth potassium citrate
  • HY-W003445
    4-Bromo-3-hydroxybenzoic acid

    		Endogenous Metabolite Neurological Disease
    4-Bromo-3-hydroxybenzoic acid is a metabolite of Brocresine and a histidine decarboxylase (HDC) inhibitor with IC50s of 1 mM for both rat fetal and rat gastric HDC. 4-Bromo-3-hydroxybenzoic acid also inhibits aromatic-L-amino acid decarboxylase from hog kidney and rat gastric mucosa in vitro with IC50s of 1 mM for both enzymes .
    4-Bromo-3-hydroxybenzoic acid
  • HY-B1330
    Proglumide

    		Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities .
    Proglumide
  • HY-103354
    Proglumide sodium

    		Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities .
    Proglumide sodium
  • HY-103354A
    Proglumide hemicalcium

    		Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide hemicalcium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide hemicalcium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide hemicalcium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide hemicalcium also has antiepileptic and antioxidant activities .
    Proglumide hemicalcium
  • HY-111313
    JNJ-26070109

    		Cholecystokinin Receptor Metabolic Disease
    JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pKis of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the research of gastroesophageal reflux disease .
    JNJ-26070109

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: